UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): June 8, 2007
REGENERON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| | | | | |
| New York | | 000-19034 | | 133444607 |
| | | | | |
(State or other jurisdiction of
incorporation) | | (Commission File Number) | | (I.R.S. Employer
Identification Number) |
| | | | | |
| 777 Old Saw Mill River Road, Tarrytown, New York | 10591-6707 |
| | | | | |
| (Address of principal executive offices) | (Zip Code) |
(914) 347-7000(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
1
Item 8.01 Other Events
On June 8, 2007, Regeneron’s President and Chief Executive Officer, Dr. Leonard Schleifer, is scheduled to present a brief report on Regeneron’s business at the company’s Annual Meeting of Shareholders to be held at the Westchester Marriott Hotel, 670 White Plains Road, Tarrytown, New York. The overheads for this presentation are furnished as Exhibit 99(a) to this Form 8-K.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
99(a) Overheads for presentation at Regeneron’s Annual Meeting of Shareholders to be held on June 8, 2007.
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | REGENERON PHARMACEUTICALS, INC.
| |
| Dated: June 8, 2007 | By: | /s/ Stuart Kolinski | |
| | | Stuart Kolinski | |
| | | Vice President and General Counsel | |
2
Exhibit Index
| | | |
| Number | | Description |
| |
| 99(a) | | Overheads for presentation at Regeneron’s Annual Meeting of Shareholders to be held on June 8, 2007. |
3
